6-K

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

For the month of November, 2009

__________

Commission File Number: 001-32371

__________

SINOVAC BIOTECH LTD.

39 Shangdi Xi Road

Haidian District

Beijing 100085, People’s Republic of China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F X                  Form 40-F _______

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):_____________

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):_____________

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes _______                    No X      

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):

82- N/A      

SINOVAC BIOTECH LTD.

Form 6-K

TABLE OF CONTENTS

	Page
Signature	3
Exhibit 99.1 – Press Release	4

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SINOVAC BIOTECH LTD.
	By:	/s/ Weidong Yin
		Name:   Weidong Yin
		Title:     Chief Executive Officer, President
Date:  November 2, 2009

EX-99.1

Exhibit 99.1

Sinovac to Transfer Stock Exchange Listing to NASDAQ Global Market

BEIJING, Nov. 3 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, announced today that it will voluntarily transfer its stock exchange listing from the NYSE Amex to the NASDAQ Global Market.

It is anticipated that Sinovac's common shares will commence trading on NASDAQ on or about November 16, 2009. Sinovac will continue to trade under the ticker symbol "SVA."

Mr. Weidong Yin, Chairman, President and CEO of Sinovac, stated, "The transfer of our stock listing to NASDAQ demonstrates our continued focus on creating shareholder value. We appreciate the support that the NYSE Amex has provided over the years. However, we believe a NASDAQ listing will provide Sinovac with opportunities to increase investor and analyst interest and provide our investors with a better environment for trading our shares. In addition, as NASDAQ is globally recognized as a leading exchange for biopharmaceutical companies, we believe a NASDAQ listing will also place us in the same marketplace as our peers."

"NASDAQ is the home of innovative biotech and healthcare companies and we are proud to welcome Sinovac, a pioneer in Chinese biotech and engineer of China's homegrown H1N1 vaccine," said Mr. Bob McCooey, Senior Vice President and Head of Global Listing of NASDAQ OMX Group.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products, including Healive® (hepatitis A), Bilive® (combined hepatitis A and B), Anflu® (influenza), Panflu(TM), Sinovac's pandemic influenza vaccine (H5N1), and PANFLU.1(TM), Sinovac's H1N1 vaccine, have already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

    For more information, please contact:

     Helen G. Yang

     Sinovac Biotech Ltd.

     Tel:   +86-10-8289-0088 x9871

     Fax:   +86-10-6296-6910

     Email: info@sinovac.com

    Investors:

     Amy Glynn/Stephanie Carrington

     The Ruth Group

     Tel:   +1-646-536-7023/7017

     Email: aglynn@theruthgroup.com

                scarrington@theruthgroup.com

    Media:

     Janine McCargo

     The Ruth Group

     Tel:   +1-646-536-7033

     Email: jmccargo@theruthgroup.com